www.ijarp.com ISSN 2456-9992 Page: 01-13
International Journal Advanced Research Publications
Review Article
Volume: 02
Issue: 07

COMPUTER-AIDED DRUG DESIGN (CADD): EMERGING TOOLS AND APPLICATIONS IN MODERN DRUG DISCOVERY

Prem Prasad[1], Ran Vijay Singh[2], Sanjay Kumar Kushwaha[3]*

[1,2]Associate Professor, Bhavdiya Institute of Pharmaceutical Sciences and Research Ayodhya-224126.

[3]Professor& Director of Bhavdiya Institute of Pharmaceutical Sciences and Research Ayodhya-224126.

Article Received: 23 May 2026, Article Revised: 11 June 2026, Published on: 01 July 2026

***Corresponding Author: Sanjay Kumar Kushwaha**
Professor& Director of Bhavdiya Institute of Pharmaceutical Sciences and Research Ayodhya-224126.
Doi: https://doi-doi.org/101555/ijarp.8342

ABSTRACT

Computer-Aided Drug Design (CADD) has become a fundamental component of modern drug discovery by accelerating the identification, optimization, and development of novel therapeutic agents while reducing both time and cost. The integration of computational techniques with experimental research has significantly improved the efficiency of lead identification and optimization, enabling researchers to predict molecular interactions, pharmacokinetic properties, and toxicity profiles before laboratory testing. CADD encompasses two principal approaches: structure-based drug design (SBDD), which utilizes the three-dimensional structure of biological targets, and ligand-based drug design (LBDD), which relies on the structural and biological information of known active compounds. Emerging tools such as molecular docking, molecular dynamics simulations, quantitative structure–activity relationship (QSAR) modeling, pharmacophore modeling, virtual screening, and artificial intelligence (AI)-driven algorithms have revolutionized the drug discovery process by enhancing predictive accuracy and facilitating the identification of promising drug candidates. In addition, advances in machine learning, deep learning, cloud computing, and big data analytics have enabled the rapid analysis of large chemical libraries and complex biological datasets, supporting precision medicine and personalized therapeutic strategies. These technologies have played a significant role in the discovery of treatments for cancer, infectious diseases, neurological disorders, and metabolic conditions. Despite remarkable progress, challenges such as limited structural data, computational complexity,

prediction reliability, and model interpretability remain important considerations. Continuous improvements in computational power, algorithm development, and multidisciplinary collaboration are expected to overcome these limitations and further strengthen the impact of CADD. This review highlights the emerging computational tools, recent technological advancements, diverse applications, and future prospects of CADD, emphasizing its transformative role in improving the speed, efficiency, and success rate of modern drug discovery and pharmaceutical research.

KEYWORDS: Computer-Aided Drug Design (CADD), Molecular Docking, Virtual Screening, Artificial Intelligence (AI), Drug Discovery.

1. INTRODUCTION

The discovery and development of new therapeutic agents is a complex, multidisciplinary, and resource-intensive process that integrates chemistry, biology, pharmacology, computational science, and clinical research. Traditionally, drug discovery has relied on extensive laboratory experimentation, high-throughput screening (HTS), and trial-and-error approaches to identify compounds with desirable pharmacological activity.**[1]** Although these conventional methods have contributed significantly to the development of life-saving medicines, they are associated with substantial financial investment, prolonged development timelines, and high attrition rates. It is estimated that the development of a single successful drug may require more than 10–15 years and cost over USD 2 billion, while the majority of candidate molecules fail during preclinical or clinical development due to poor efficacy, unfavorable pharmacokinetic properties, or unexpected toxicity.**[2]** These challenges have driven the pharmaceutical industry toward innovative computational approaches capable of improving the efficiency, accuracy, and success rate of modern drug discovery.Computer-Aided Drug Design (CADD) has emerged as one of the most influential technological advancements in pharmaceutical research, transforming the way novel therapeutic compounds are identified, optimized, and evaluated. CADD employs computational algorithms, molecular modeling techniques, and artificial intelligence-based methodologies to predict molecular interactions between drug candidates and biological targets before experimental validation. By integrating structural biology, cheminformatics, bioinformatics, molecular pharmacology, and computational chemistry, CADD enables researchers to rationally design molecules with enhanced biological activity, improved selectivity, and reduced toxicity.**[3]** Consequently, computational drug discovery has become an

indispensable component of both academic research and industrial pharmaceutical development.The concept of computational drug design originated during the latter half of the twentieth century with the availability of protein crystal structures and advances in molecular graphics. Over the past few decades, remarkable improvements in computational power, structural biology, and algorithm development have revolutionized this field. The completion of the Human Genome Project, advances in X-ray crystallography, cryogenic electron microscopy (Cryo-EM), nuclear magnetic resonance (NMR) spectroscopy, and the rapid growth of publicly accessible biological and chemical databases have further expanded the scope of CADD. More recently, breakthroughs in artificial intelligence (AI), machine learning (ML), deep learning (DL), cloud computing, and quantum computing have significantly accelerated computational drug discovery, enabling the rapid analysis of millions of chemical compounds and complex biological datasets.**[4]**Computer-Aided Drug Design is broadly classified into two principal approaches: Structure-Based Drug Design (SBDD) and Ligand-Based Drug Design (LBDD). Structure-Based Drug Design utilizes the three-dimensional structure of biological targets, such as enzymes, receptors, or nucleic acids, to identify molecules capable of binding effectively within the active site. Techniques such as molecular docking, molecular dynamics (MD) simulations, binding free-energy calculations, and structure-based virtual screening play a central role in this approach. In contrast, Ligand-Based Drug Design is employed when the three-dimensional structure of the target protein is unavailable. This strategy relies on information obtained from known biologically active compounds and utilizes computational techniques such as pharmacophore modeling, quantitative structure–activity relationship (QSAR) analysis, similarity searching, and ligand-based virtual screening to identify new drug candidates.**[5]**

The integration of emerging computational technologies has dramatically expanded the applications of CADD across multiple therapeutic areas. Molecular docking facilitates the prediction of ligand–protein interactions and binding affinities, while molecular dynamics simulations provide valuable insights into the dynamic behavior and stability of biomolecular complexes under physiological conditions. Virtual screening enables the rapid evaluation of extensive chemical libraries, allowing researchers to prioritize promising lead compounds for experimental testing. Pharmacophore modeling and QSAR techniques assist in understanding the structural features responsible for biological activity, thereby guiding lead optimization. Collectively, these methodologies significantly reduce experimental workload and increase the probability of identifying successful drug candidates.**[6]**

In recent years, artificial intelligence and machine learning have introduced a new paradigm in computational drug discovery. AI-driven algorithms are capable of analyzing vast chemical and biological datasets to identify hidden patterns, predict molecular properties, optimize lead compounds, estimate absorption, distribution, metabolism, excretion, and toxicity (ADMET) profiles, and even generate entirely novel chemical structures with desired pharmacological characteristics. Deep learning architectures, including graph neural networks, transformer-based models, and generative adversarial networks, have further enhanced predictive accuracy and accelerated various stages of the drug discovery pipeline.**[7]** These innovations have gained particular importance in addressing emerging infectious diseases, rare genetic disorders, cancer, neurodegenerative diseases, and antimicrobial resistance. The practical significance of CADD has been demonstrated through its contribution to the discovery and optimization of numerous clinically relevant drugs. During the COVID-19 pandemic, computational approaches played a crucial role in identifying potential inhibitors against SARS-CoV-2 proteins through virtual screening, molecular docking, and drug repurposing strategies.**[8]** Similarly, CADD has substantially contributed to the development of targeted anticancer agents, kinase inhibitors, antiviral drugs, anti-inflammatory compounds, and precision medicine approaches by facilitating the identification of highly selective therapeutic molecules with improved efficacy and safety profiles.Despite these remarkable achievements, several challenges continue to limit the widespread implementation of computational drug design. The accuracy of computational predictions depends heavily on the availability of high-quality structural data, reliable biological datasets, and robust predictive algorithms. Limitations in force fields, scoring functions, protein flexibility, molecular complexity, computational costs, and experimental validation remain significant obstacles.**[9]** Moreover, issues related to data bias, model interpretability, reproducibility, and regulatory acceptance require continuous methodological improvements. Addressing these limitations will require interdisciplinary collaboration among computational scientists, medicinal chemists, structural biologists, pharmacologists, and data scientists.**[10]**

This review provides a comprehensive overview of Computer-Aided Drug Design, highlighting its fundamental principles, classification, emerging computational tools, artificial intelligence-driven methodologies, databases, software platforms, and diverse applications in modern drug discovery. Furthermore, recent technological advances, ADMET prediction strategies, current challenges, and future perspectives are discussed to emphasize

the transformative role of CADD in accelerating pharmaceutical innovation and facilitating the development of safer, more effective, and personalized therapeutic agents.

2. Fundamentals of Computer-Aided Drug Design (CADD)

Computer-Aided Drug Design (CADD) is a multidisciplinary scientific approach that employs computational methods to facilitate the discovery, design, optimization, and evaluation of novel therapeutic agents. It integrates principles from medicinal chemistry, computational chemistry, structural biology, bioinformatics, cheminformatics, pharmacology, and molecular biology to accelerate drug discovery while minimizing experimental costs and development time.**[11]** By utilizing advanced computational algorithms, molecular modeling techniques, and large biological databases, CADD enables researchers to predict molecular interactions, optimize lead compounds, evaluate pharmacokinetic properties, and identify potential safety concerns before laboratory experimentation. Consequently, CADD has become an indispensable component of modern pharmaceutical research and development.The primary objective of CADD is to identify chemical compounds that exhibit high affinity and specificity toward a particular biological target while possessing favorable pharmacokinetic and toxicity profiles.**[12]** Drug molecules exert their therapeutic effects by interacting with biological macromolecules such as enzymes, receptors, ion channels, nucleic acids, or transport proteins. Understanding these molecular interactions is fundamental to rational drug design. Computational methods simulate these interactions at the atomic level, allowing researchers to estimate binding affinity, predict molecular conformations, identify critical amino acid residues involved in ligand binding, and evaluate the stability of drugtarget complexes under physiological conditions.The foundation of CADD lies in the principle that biological activity is directly related to molecular structure. According to the structure–activity relationship (SAR), even minor modifications in the chemical structure of a molecule can significantly influence its pharmacological activity, selectivity, metabolism, and toxicity. **[13]**This targeted strategy not only minimizes resource utilization but also increases the probability of identifying potent lead compounds. Additionally, computational approaches facilitate drug repurposing by identifying new therapeutic applications for existing approved drugs, thereby shortening development timelines and reducing regulatory risks.The increasing availability of biological databases and computational resources has further enhanced the capabilities of CADD. Public repositories such as Protein Data Bank (PDB), PubChem, ChEMBL, DrugBank, and ZINC provide researchers with access to millions of chemical structures, protein conformations, pharmacological data, and molecular

descriptors. These resources, combined with powerful computational software, cloud computing, and artificial intelligence, have enabled large-scale virtual screening and predictive modeling at unprecedented speed and accuracy.**[14]**Despite its remarkable advantages, CADD is not intended to replace experimental drug discovery but rather to complement it. Computational predictions remain dependent on the quality of available structural data, accuracy of mathematical models, and reliability of scoring functions. Experimental validation through biochemical assays, cell-based studies, animal models, and clinical trials remains essential for confirming computational findings and ensuring the safety and efficacy of candidate drugs.Overall, the fundamental principles of Computer-Aided Drug Design provide the scientific basis for rational drug discovery by integrating computational prediction with experimental validation.**[15]** Through the application of molecular modeling, bioinformatics, cheminformatics, and artificial intelligence, CADD has transformed pharmaceutical research into a faster, more efficient, and increasingly data-driven process. As computational technologies continue to evolve, the role of CADD is expected to expand further, contributing significantly to the development of safer, more effective, and personalized therapeutic agents.**[16]**

3. Classification of Computer-Aided Drug Design (CADD)

Computer-Aided Drug Design (CADD) is broadly classified into two major approaches: Structure-Based Drug Design (SBDD) and Ligand-Based Drug Design (LBDD). The selection of an appropriate approach primarily depends on the availability of structural information regarding the biological target.Structure-Based Drug Design (SBDD) is employed when the three-dimensional (3D) structure of the target protein or receptor is available through experimental techniques such as X-ray crystallography, cryo-electron microscopy (Cryo-EM), nuclear magnetic resonance (NMR) spectroscopy, or computational prediction methods like AlphaFold.**[17]** SBDD focuses on understanding the molecular interactions between the target and potential ligands to identify compounds with high binding affinity and specificity. Common techniques used in this approach include molecular docking, molecular dynamics (MD) simulations, de novo drug design, binding free-energy calculations, and structure-based virtual screening. SBDD has become an essential strategy for rational drug discovery and lead optimization.Ligand-Based Drug Design (LBDD) is applied when the three-dimensional structure of the biological target is unavailable.**[18]** Instead, this approach relies on the structural and biological information of known active compounds to predict the activity of new molecules. LBDD employs computational

techniques such as pharmacophore modeling, quantitative structure–activity relationship (QSAR) analysis, molecular similarity searching, and ligand-based virtual screening. These methods help identify key structural features responsible for biological activity and facilitate the design of novel compounds with improved therapeutic potential.In recent years, hybrid CADD approaches have gained considerable attention by integrating both SBDD and LBDD with artificial intelligence (AI) and machine learning (ML) techniques. These combined strategies improve prediction accuracy, enhance lead optimization, and accelerate the discovery of safer.**[19]**

Classification of CADD.



Emerging Computational Tools in Computer-Aided Drug Design (CADD)

Emerging computational tools are transforming the field of Computer-Aided Drug Design (CADD) by making the drug discovery process faster, more accurate, and cost-effective. Artificial Intelligence (AI) and Machine Learning (ML) are widely used to predict biological activity, identify potential drug candidates, and optimize lead compounds by analyzing large datasets. Deep learning models improve molecular property prediction and accelerate virtual screening.Molecular Dynamics (MD) simulation has become an essential tool for studying the dynamic behavior of proteins and drug molecules, providing insights into molecular interactions and binding stability.**[20]** Quantum Mechanics (QM) and QM/MM methods enable accurate prediction of electronic properties and reaction mechanisms, which are important for designing highly specific drugs.Cloud computing and High-Performance Computing (HPC) allow researchers to perform complex simulations and analyze massive datasets in a shorter time. Big data analytics integrates genomic, proteomic, and clinical data to identify novel therapeutic targets and support personalized medicine.**[21]** In addition, generative AI models can design new drug-like molecules with desired pharmacological properties, significantly reducing the time required for lead discovery.These emerging

computational tools have revolutionized modern drug discovery by improving prediction accuracy, reducing experimental costs, minimizing failure rates, and accelerating the development of safe and effective therapeutic agents.**[22]**

S. No.	Emerging Computational Tool	Description	Reference
1	Artificial Intelligence (AI)	AI accelerates drug discovery by predicting biological activity, identifying drug targets, and optimizing lead compounds.	**[23]**
2	Machine Learning (ML)	ML analyzes large datasets to predict molecular properties, toxicity, and drug efficacy with high accuracy.	**[24]**
3	Deep Learning	Deep learning models improve virtual screening, molecular property prediction, and de novo drug design.	**[25]**
4	Molecular Dynamics (MD) Simulation	MD simulation studies the movement and stability of protein–ligand complexes over time, providing insights into binding mechanisms.	**[26]**
5	Quantum Mechanics (QM/MM)	QM/MM methods accurately predict electronic interactions , mechanisms in drug molecules.	**[27]**
6	High-Performance Computing (HPC)	HPC enables rapid execution of largescale molecular simulation computational analyses.	**[28]**
7	Big Data Analytics	Integrates genomic, proteomic, and clinical data to identify novel drug targets and support precision medicine.	**[29]**
8	Generative AI	Generates novel drug-like molecules with desired biological and physicochemical properties, reducing drug development time.	**[30]**

ADMET Prediction

ADMET prediction refers to the computational evaluation of a drug candidate's Absorption, Distribution, Metabolism, Excretion, and Toxicity properties before experimental testing. It is a crucial step in Computer-Aided Drug Design (CADD) because it helps identify compounds with favorable pharmacokinetic and safety profiles at an early stage of drug discovery. Various in silico tools and machine learning algorithms are used to predict parameters such as intestinal absorption, blood–brain barrier permeability, plasma protein binding, cytochrome P450 metabolism, renal clearance, and potential toxicity.**[31]** Early ADMET assessment reduces the likelihood of late-stage drug failure, minimizes the need for animal testing, and lowers research costs. By eliminating compounds with poor pharmacokinetic or toxicological

properties, ADMET prediction improves lead optimization and increases the probability of developing safe, effective, and successful therapeutic agents.**[32]**

Recent Advances

Recent advances in Computer-Aided Drug Design (CADD) have significantly improved the efficiency and success of drug discovery. Artificial Intelligence (AI) and Machine Learning (ML) are increasingly used for virtual screening, lead optimization, and prediction of drug–target interactions.**[33]** Deep learning models can rapidly analyze large chemical libraries and identify promising drug candidates with high accuracy. Advances in molecular dynamics simulations have enabled researchers to better understand protein flexibility and ligand binding mechanisms. Cloud computing and High-Performance Computing (HPC) have accelerated complex molecular simulations, while generative AI has facilitated the design of novel drug-like molecules with desired pharmacological properties. Additionally, the integration of multi-omics data, including genomics, proteomics, and metabolomics, has supported precision medicine and target identification.**[34]** These innovations have reduced the time, cost, and failure rate associated with traditional drug discovery.

Challenges

Despite its advantages, CADD faces several challenges. The accuracy of computational predictions depends on the availability and quality of experimental data. Incomplete or biased datasets can lead to unreliable models and incorrect predictions. Predicting protein flexibility, binding affinity, and complex biological interactions remains difficult. Many computational methods require substantial computational resources, specialized software, and technical expertise, which may not be available in all research settings. Furthermore, AI and machine learning models often lack interpretability, making it challenging to understand the basis of their predictions. Another major limitation is that in silico results must always be validated through in vitro and in vivo experiments before clinical application. Overcoming these challenges requires improved algorithms, high-quality datasets, interdisciplinary collaboration, and continuous validation with experimental studies.

Future Perspectives

The future of Computer-Aided Drug Design is expected to be driven by advances in Artificial Intelligence, quantum computing, and big data analytics. More accurate predictive models, digital twins, and personalized medicine approaches will enable the development of safer and more effective drugs tailored to individual patients. Integration of AI with molecular

simulations, multi-omics data, and automated laboratory platforms is expected to further accelerate drug discovery. As computational methods continue to evolve, CADD will play an increasingly important role in reducing development time, lowering research costs, and improving the success rate of new therapeutic agents.

CONCLUSION

Computer-Aided Drug Design (CADD) has emerged as one of the most significant technological advancements in pharmaceutical research and drug discovery. By integrating computational chemistry, molecular biology, bioinformatics, and artificial intelligence, CADD has revolutionized the traditional drug development process, making it faster, more accurate, and cost-effective. Unlike conventional drug discovery methods, which require extensive laboratory experiments and significant financial investment, CADD enables researchers to identify, design, and optimize potential drug candidates using computational approaches before experimental validation.The application of techniques such as structure-based drug design (SBDD), ligand-based drug design (LBDD), molecular docking, virtual screening, pharmacophore modeling, quantitative structure–activity relationship (QSAR), molecular dynamics simulation, and ADMET prediction has significantly improved the efficiency of lead identification and optimization. These computational methods help researchers understand drug–target interactions, predict pharmacokinetic and toxicological properties, and eliminate compounds with poor therapeutic potential during the early stages of development. Consequently, CADD reduces the number of failed drug candidates in later phases, shortens the drug development timeline, and lowers overall research costs.Recent advancements in Artificial Intelligence (AI), Machine Learning (ML), deep learning, cloud computing, and high-performance computing have further expanded the capabilities of CADD. These emerging technologies enable the analysis of massive biological and chemical datasets, facilitate the prediction of molecular properties with greater accuracy, and support the design of novel drug molecules with improved efficacy and safety. Furthermore, the integration of genomics, proteomics, metabolomics, and other multi-omics data has strengthened target identification and promoted the development of precision medicine, where therapies can be tailored to individual patient characteristics.Despite its numerous advantages, CADD still faces challenges related to data quality, prediction accuracy, computational complexity, and the need for experimental validation. Reliable computational models depend on high-quality biological and chemical data, and in silico predictions must always be confirmed through in vitro, in vivo, and clinical studies before therapeutic

application. Therefore, computational approaches should be considered complementary to experimental research rather than complete replacements.

In conclusion, CADD has become an indispensable component of modern drug discovery and pharmaceutical research. Continuous innovations in computational methods, artificial intelligence, and molecular modeling are expected to further improve the speed, precision, and success rate of drug development. As these technologies continue to evolve, CADD will play an increasingly important role in discovering safer, more effective, and personalized therapeutic agents, ultimately contributing to improved healthcare outcomes and addressing the growing global demand for innovative medicines.

REFERENCES

2. Anderson, A. C. (2003). The process of structure-based drug design. *Chemistry & Biology, 10*(9), 787–797.
3. Bajorath, J. (2002). *Chemoinformatics: Concepts, Methods, and Tools for Drug Discovery*. Humana Press.
4. Brown, N. (Ed.). (2020). *Artificial Intelligence in Drug Discovery*. Royal Society of Chemistry.
5. Cavasotto, C. N., & Phatak, S. S. (2009). Homology modeling in drug discovery. *Drug Discovery Today, 14*(13–14), 676–683.
6. Chandra, S., & Kumar, A. (2019). Applications of molecular docking in drug discovery. *Current Computer-Aided Drug Design, 15*(2), 123–134.
7. DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016). Innovation in the pharmaceutical industry: New estimates of R&D costs. *Journal of Health Economics, 47*, 20–33.
8. Ferreira, L. G., dos Santos, R. N., Oliva, G., & Andricopulo, A. D. (2015). Molecular docking and structure-based drug design strategies. *Molecules, 20*(7), 13384–13421.
9. Ganesan, A. (2008). The impact of natural products upon modern drug discovery. *Current Opinion in Chemical Biology, 12*(3), 306–317.
10. Gohlke, H., & Klebe, G. (2002). Approaches to the description and prediction of binding affinity. *Angewandte Chemie International Edition, 41*(15), 2644–2676.
11. Goodsell, D. S., Morris, G. M., & Olson, A. J. (1996). Automated docking of flexible ligands. *Journal of Molecular Recognition, 9*(1), 1–5.
12. Hughes, J. P., Rees, S., Kalindjian, S. B., & Philpott, K. L. (2011). Principles of early drug discovery. *British Journal of Pharmacology, 162*(6), 1239–1249.

13. Kitchen, D. B., Decornez, H., Furr, J. R., &Bajorath, J. (2004). Docking and scoring in virtual screening. *Nature Reviews Drug Discovery, 3*(11), 935–949.
14. Kuntz, I. D. (1992). Structure-based strategies for drug design. *Science, 257*(5073), 1078–1082.
15. Leach, A. R. (2001). *Molecular Modelling: Principles and Applications* (2nd ed.). Pearson Education.
16. Leach, A. R., Gillet, V. J., & Lewis, R. A. (2009). *An Introduction to Chemoinformatics*. Springer.
17. Lionta, E., Spyrou, G., Vassilatis, D. K., &Cournia, Z. (2014). Structure-based virtual screening for drug discovery. *Current Topics in Medicinal Chemistry, 14*(16), 1923–1938.
18. Lipinski, C. A. (2004). Lead- and drug-like compounds: The rule-of-five revolution. *Drug Discovery Today: Technologies, 1*(4), 337–341.
19. Macalino, S. J. Y., Gosu, V., Hong, S., & Choi, S. (2015). Role of computer-aided drug design in modern drug discovery. *Archives of Pharmacal Research, 38*(9), 1686–1701.
20. Meng, X. Y., Zhang, H. X., Mezei, M., & Cui, M. (2011). Molecular docking: A powerful approach for structure-based drug discovery. *Current Computer-Aided Drug Design, 7*(2), 146–157.
21. Morris, G. M., Huey, R., Lindstrom, W., et al. (2009). AutoDock4 and AutoDockTools4. *Journal of Computational Chemistry, 30*(16), 2785–2791.
22. Patrick, G. L. (2017). *An Introduction to Medicinal Chemistry* (6th ed.). Oxford University Press.
23. Sliwoski, G., Kothiwale, S., Meiler, J., & Lowe, E. W. (2014). Computational methods in drug discovery. *Pharmacological Reviews, 66*(1), 334–395.
24. Schneider, G. (2018). Automating drug discovery. *Nature Reviews Drug Discovery, 17*(2), 97–113.
25. Shoichet, B. K. (2004). Virtual screening of chemical libraries. *Nature, 432*(7019), 862–865.
26. Trott, O., & Olson, A. J. (2010). AutoDock Vina: Improving the speed and accuracy of docking. *Journal of Computational Chemistry, 31*(2), 455–461.
27. Vamathevan, J., Clark, D., Czodrowski, P., et al. (2019). Applications of machine learning in drug discovery and development. *Nature Reviews Drug Discovery, 18*(6), 463–477.

28. Walters, W. P., & Murcko, M. A. (2020). Assessing the impact of generative AI on medicinal chemistry. *Nature Biotechnology, 38*(2), 143–145.
29. Wermuth, C. G. (Ed.). (2015). *The Practice of Medicinal Chemistry* (4th ed.). Academic Press.
30. Wishart, D. S. (2006). DrugBank: A comprehensive resource for in silico drug discovery. *Nucleic Acids Research, 34*, D668–D672.
31. Yuriev, E., Agostino, M., & Ramsland, P. A. (2011). Challenges and advances in molecular docking. *Journal of Molecular Recognition, 24*(2), 149–164.
32. Ekins, S. (2007). *Computer Applications in Pharmaceutical Research and Development*. John Wiley & Sons.
33. Gasteiger, J., & Engel, T. (2003). *Chemoinformatics: A Textbook*. Wiley-VCH.
34. Cramer, R. D. (2003). The impact of computational chemistry on drug discovery. *Journal of Medicinal Chemistry, 46*(18), 3747–3753.
35. Kumar, A., & Zhang, K. Y. J. (2018). Advances in the development of computational methods for drug discovery. *Frontiers in Chemistry, 6*, 1–15.